TWO-YEAR FATE STUDY OF PACATAL-TREATED PATIENTS
Abstract
It may be implied from the data collected that tolerance formation does not occur and that the maintenance dosage is substantially smaller than the original therapeutic dosage. There is no evidence of continued toxicity and those patients treated continuously with Pacatal for 3 years are remarkably free of side effects. Remission following Pacatal therapy appears to be a stable one and only 8¼% of the released patients have found it necessary to return to the hospital.
The findings in this study are similar to those obtained in a 2-year follow-up study of Thorazine-treated patients.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
